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Abstract
This paper presents the updated Polish Neuroendocrine Tumour Network expert panel recommendations on the management of neu-
roendocrine neoplasms (NENs) of the stomach and duodenum, including gastrinoma. The recommendations discuss the epidemiology, 
pathogenesis and clinical presentation of these tumours as well as their diagnosis, including biochemical, histopathological and localisa-
tion diagnosis. The principles of treatment are discussed, including endoscopic, surgical, pharmacological and radionuclide treatment. 
Finally, recommendations on patient monitoring are given. (Endokrynol Pol 2013; 64 (6): 444–458)
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Streszczenie
W niniejszej pracy przedstawiono uaktualnione zalecenia grupy ekspertów Polskiej Sieci Guzów Neuroendokrynnych dotyczące 
zasad postępowania w nowotworach neuroendokrynnych żołądka i dwunastnicy z uwzględnieniem gastrinoma. Omówiono epide-
miologię, patogenezę i obraz kliniczny tych nowotworów. Przedstawiono zalecenia dotyczące zasad postępowania diagnostycznego, 
z uwzględnieniem diagnostyki biochemicznej, histopatologicznej oraz lokalizacyjnej. Uwzględniono także zasady postępowania 
terapeutycznego, w tym leczenie endoskopowe i chirurgiczne, oraz omówiono możliwości leczenia farmakologicznego i radioizotopo-
wego. Przedstawiono także zalecenia odnośnie monitorowania chorych z NEN żołądka, dwunastnicy z uwzględnieniem gastrinoma. 
(Endokrynol Pol 2013; 64 (6): 444–458)
Słowa kluczowe: nowotwory neuroendokrynne; żołądek; dwunastnica; gastrinoma; diagnostyka; terapia; zalecenia
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1. Epidemiology and pathogenesis
1.1. Neuroendocrine neoplasms of the stomach
Neuroendocrine neoplasms (NEN) constitute ap-
proximately 1% of all neoplasms of the stomach, and 
approximately 23% of all gastrointestinal tumours of 
this type [1]. The prevalence is estimated as 1–2 cases 
per 1,000,000 people per year, without any significant 
predominance of either sex (1.2/1,000,000 males, 
1.8/1,000,000 females). In recent years there has been 
an 8–9-fold increase in the incidence of gastric NENs 
(g-NENs) as a result of increased detectability due 
to the availability of endoscopic techniques [2]. In 
the stomach, four clinical and pathogenetic types of 
g-NENs are found, with differences in the clinical and 
histopathological picture, as well as in diagnostic and 
therapeutic management.
Pathogenesis
Type 1 and 2 tumours arise from the enterochromatof-
fin-like (ECL) cells of the gastric mucosa in response to 
chronic, excessive secretion of gastrin. Secondary hy-
pergastrinemia, caused by achlorhydria accompanying 
atrophic gastritis, is responsible for the development of 
g-NENs type 1. Primary hypergastrinemia in Zollinger-
Ellison syndrome (ZES), occasional or associated with 
multiple endocrine neoplasia 1 (MEN1), is responsible 
for type 2 g-NENs. Gastrin and its derivatives stimulate 
proliferation, migration and differentiation of ECL cells, 
which leads to their hyperplasia and dysplasia [2]. In 
patients with MEN1, the transforming factor can be a 
menin defect. In the course of atrophic gastritis, no such 
factor has been determined. It is possible that protein 
inhibiting apoptosis BCL2, protein 53 (p53), fibroblast 
growth factor (FGF), transforming growth factor-α 
(TGF-α), and incorrect function of the REGL protein (in-
hibiting proliferation of ECL cells) could play a role [3].
Type 1
Gastric neuroendocrine neoplasms type 1 (70–80% of g-
NENs) are associated with atrophic gastritis. They occur 
in less than 1% of patients, more often in women, and 
are diagnosed mostly between the ages of 40 and 60. In 
the future, the availability of endoscopic examination 
and conducting gastroscopy in patients with autoim-
mune diseases will lower the age of patients diagnosed 
with type 1 g-NEN [4,5].
They are diagnosed during an endoscopic examina-
tion performed due to dyspeptic symptoms or anaemia, 
more frequently due to macrocytic than iron-deficiency 
anaemia [5]. 65% of cases are multiple polyps of < 1 cm 
in diameter or microcarcinoids found in the gastric 
mucosa. In 70–85% they belong to the NEN G1 group, 
according to the World Health Organisation (WHO) 
2010 classification [6, 7]. They are rarely invasive [2]. 
They are almost always slowly growing tumours with 
a good prognosis (up to 100% of patients with ten-year 
survival). They are non-functional, although less than 
1% of patients with type 1 g-NENs present the symp-
toms of atypical carcinoid syndrome.
Type 2
This type constitutes 5–6% of gastric neuroendocrine tu-
mours. It is a response to hypergastrinemia in the course 
of duodenal or pancreatic gastrinoma. In 23–29% of 
cases, it is part of MEN1 syndrome. In 1–3% of patients, 
it is a sporadic form of gastrinoma [2, 5, 8]. Zollinger-
Ellison syndrome (ZES) is clinically present. Neoplasms 
are usually small (< 1–2 cm) and frequently multiple, 
located in the fundus and body of the stomach, only 
occasionally in the gastric cardia. They are classified as 
well-differentiated NENs (G1/G2 according to WHO 
2010), with a good prognosis, regardless of the presence 
of metastases in as many as 35% of patients at the time 
of diagnosis [8].
Type 3
They are tumours occurring in 14–25% of cases, with-
out any specific predisposing factors. They are more 
frequent in males over 50 years of age. They are single, 
of > 2 cm in diameter, with ulceration on the surface, 
located in the fundus and body of the stomach. They are 
classified as gastric neuroendocrine carcinomas (g-NEC 
according to WHO 2010). In 100% they are associated 
with metastases to the regional lymph nodes and liver. 
Deaths due to g-NEC occur in 25–87% of cases, depend-
ing on the level of differentiation and the presence of 
metastases [1].
Type 4
Presently, a division of gastric neuroendocrine neo-
plasms type 3 into subtypes 3 and 4 is suggested. Type 
3 includes sporadic, non-functional tumours, whereas 
type 4 constitute poorly differentiated carcinomas, or 
carcinomas arising from cells producing ACTH, sero-
tonin, as well as mixed, endo-exocrine carcinomas [2, 
5]. From the clinical point of view, the clinical course 
of neoplasms type 3 and 4 is similar, and the division 
is of limited consequence for the choice of treatment.
1.2. Duodenal neuroendocrine neoplasms
According to American statistics, they constitute 
2–3% of all gastrointestinal tumours [2, 9]. In 50–70% 
they are well-differentiated NENs (G1 according to 
WHO 2010). Five types of duodenal neuroendocrine 
neoplasms (d-NEN) can be distinguished [9]. They in-
clude: i) gastrinoma (27–58%); ii) non-functional neo-
plasms with positive results of immunohistochemical 
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tests for serotonin and calcitonin; iii) somatostatin 
(SST) secreting tumours (23–75%); iv) poorly dif-
ferentiated duodenal carcinomas; and v) neoplasms 
of the gangliocytic paraganglioma type (rare). Some 
authors exclude from this group tumours located 
in the ampulla of Vater and its area (approximately 
20% of NENs), whose clinical course rather resembles 
pancreatic neoplasms [9]. Over 90% of NENs are 
located in the duodenal bulb (58%) and descending 
duodenum (33%). Tumours belonging to d-NENs are 
usually small (1.2–1.5 cm), limited to the mucosa and 
submucosa, but at the moment of diagnosis in 40–60% 
of cases regional lymph nodes metastases are present. 
Hepatic metastases occur in less than 10% of patients. 
Multiple d-NENs suggest MEN1 [8].
2. Clinical characteristics
2.1. Gastric neuroendocrine neoplasms
Type 1 g-NENs are not characterised by a specific clini-
cal picture. It is usually diagnosed during gastroscopy 
performed due to dyspeptic symptoms. The course 
of the disease is usually mild, and after endoscopic or 
surgical treatment it only requires a periodic endoscopic 
surveillance [6].
In type 2 g-NENs, the symptoms of ZES dominate 
(described for gastrinoma). Screening tests for MEN1 syn-
drome, described in the General Section, are necessary [8].
G-NECs are clinically manifested by abdominal pains, 
anaemia and weight loss. Their course is malignant and 
they are usually disseminated at the diagnosis [3].
Gastric neuroendocrine neoplasms very rarely 
(< 1%) present the symptoms of atypical carcinoid 
syndrome (concomitant hepatic metastases). Flushing 
usually lasts longer and is accompanied by lacrima-
tion, often with lowered arterial pressure. Unlike the 
typical carcinoid syndrome, excess histamine can cause 
overgrowth of the facial skin (‘leonine facies’) and its 
bruising. Endocardial damage may also occur [10].
2.2. Duodenal neuroendocrine neoplasms
2.2.1. Gastrinoma
Gastrinomas are neuroendocrine neoplasms located in 
the duodenum (70%), pancreas (25%), and rarely (5%) 
in other sites (stomach, liver, ovary, lung), secreting gas-
trin and causing clinical ZES. Hypergastrinemia results 
in hypersecretion of gastric acid, and, consequently, in 
peptic ulcer disease and gastroesophageal reflux disease 
with a severe course [11, 12].
Gastrinomas are well-differentiated neoplasms 
(NEN G1/G2).
Depending on their location and possible concomi-
tant MEN1, gastrinomas can be characterised as follows 
[8, 12–14].
Duodenal gastrinomas:
 — 50–88% of gastrinomas in sporadic form are located 
in the duodenum;
 — 70–100% of gastrinomas in MEN1 are located in the 
duodenum;
 — are small (77% < 1 cm);
 — demonstrate local invasiveness;
 — are usually located in the duodenal bulb and de-
scending duodenum;
 — are associated with metastases to the nearest lymph 
nodes;
 — hepatic metastases are rare (5–10%).
Pancreatic gastrinomas:
 — are large (on average 3.8 cm, 6% < 1 cm);
 — can be located in any part of the pancreas;
 — are associated with frequent hepatic metastases 
(25–35%).
Gastrinoma in the course of MEN1/ZES:
 — 20–30% of patients with ZES are diagnosed with 
MEN1;
 — MEN1/ZES in 70–100% are situated in the duode-
num, tumours are almost always multiple;
 — 15% demonstrate aggressive clinical course;
 — the average age at diagnosis is 32–35 years (for the 
sporadic form: 48–55 years);
 — in 45% of patients, ZES symptoms precede by a few 
years symptomatic hypercalcemia;
 — in 25% of MEN1/ZES patients, the family history of 
MEN1 is negative.
Zollinger-Ellison syndrome should be suspected in 
patients [12]:
 — with multiple ulcers of the upper part of the gastro-
intestinal tract, with unusual location;
 — with relapses after treatment;
 — with concomitant severe oesophagitis;
 — with negative H. pylori test results;
 — with complications of the disease (gastrointestinal 
tract perforation, bleeding);
 — with diarrhoea;
 — with thickening of the gastric folds (present in 92% 
of ZES patients).
The most common symptoms include persistent 
pain in the upper abdomen (in 66% of patients), nausea 
(in 38%), vomiting (in 24%), diarrhoea (in 76%), which 
disappears after the use of protein pump inhibitors 
(PPI) — a very characteristic feature — weight loss (in 
12%), and gastrointestinal bleeding. There are no dif-
ferences between the clinical symptoms of pancreatic 
and duodenal gastrinoma [12].
Helicobacter pylori infection is less frequent in ZES 
patients (in 24–48% of patients) compared to idiopathic 
peptic ulcer disease (in 90% of patients). Therefore, 
negative results of H. pylori tests in patients with 
recurrent peptic ulcer disease who do not receive 
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NSAIDs or acetylsalicylic acid should be suggestive 
of gastrinoma [15].
ZES diagnosis requires the evidence of hypergas-
trinemia under fasted conditions, with hypersecretion 
of hydrochloric acid, or low gastric pH (pH < 2). In 
practice, the diagnostics starts with determination of 
serum gastrin level under fasted conditions (FSG), 
which is increased in 98% of ZES patients. The evidence 
of hypergastrinemia is not sufficient to diagnose ZES, 
as there are reasons for increased gastrin level other 
than gastrinoma [5, 8]:
 — with hypo/achlorhydria — atrophic gastritis, using 
PPI;
 — with hyperchlorhydria: H. pylori infection, pyloric 
stenosis, renal failure, antral G-cell syndromes, short 
bowel syndrome.
In 40–60% of patients with ZES, FSG value is lower 
than ten times the normal gastrin level under fasted 
conditions, and it is comparable to gastrin levels in the 
course of H. pylori infection.
Therefore, the effective eradication of H. pylori is 
necessary before gastrinoma diagnosis can be estab-
lished [8].
Proton pump inhibitors (PPI) and histamine H2-
receptor antagonists increase gastrin and CgA levels 
in the blood, so PPI should be discontinued 10–14 days 
before the planned test. In patients with suspected 
gastrinoma, PPI can be substituted in this period with 
oral H2-receptor antagonists, but it is recommended 
that they are also discontinued at least 48 hours before 
the examination [8].
Gastrinoma can be diagnosed if the gastrin levels 
under fasted conditions are over ten times the up-
per limit of normal, and gastric pH is < 2. In most 
cases, increased gastrin level is accompanied by 
increased serum CgA concentration. The blood for 
gastrin determination should be drawn under fasted 
conditions. If gastrin concentration under fasted 
conditions is increased less than ten times, and pH 
of the gastric juice is ≤ 2, the secretin stimulation 
test should be performed. Secretin is administered 
under fasted conditions, intravenously, at a dose of 
2.0 units/kg bw. Gastrin is determined at proper in-
tervals, expressed in minutes relative to the moment 
of secretin administration: –15 min, –1 min, +2 min, 
+5 min, +10 min, +15 min, +20 min, and +30 min. 
Gastrinoma diagnosis is confirmed by an increase in 
gastrin level by more than 120 pg/mL, at any point 
of the test, in relation to the baseline value. For this 
value of increase in gastrin concentration, the sen-
sitivity of the secretin stimulation test is 94%, and 
the specificity is 100%. Increasing the value of the 
diagnostic gastrin increment to 200 pg/mL reduces 
the test sensitivity to 82% [8].
The gastrin stimulation test with intravenous 
calcium gluconate is less sensitive, less specific and 
associated with more adverse reactions. It is rarely 
performed, only if conducting the secretin stimulation 
test is impossible or if its result is negative, while the 
clinical suspicion of gastrinoma is strong [16].
Determination of gastrin level on consecutive days 
demonstrates the referential values in less than 0.5% 
of patients with ZES. Gastric juice pH above 3, on the 
other hand, is a strong indicator excluding the presence 
of gastrinoma. As in 20–25% of cases gastrinoma is an 
element in MEN1 syndrome, every patient with ZES 
should undergo screening tests for MEN1 described in 
General Recommendations.
The clinical course is aggressive in approximately 
25% of sporadic and 15% of ZES/MEN1 gastrinoma 
patients. The following constitute poor prognostic 
factors [16]:
 — inadequate control of gastric acid hypersecretion,
 — liver metastases,
 — female sex,
 — sporadic form,
 — short time interval between initial symptoms and 
diagnosis,
 — very high FSG,
 — large size (1–3 cm) of the primary tumour,
 — pancreatic location of the primary tumour,
 — ectopic ACTH secretion in the course of gastrinoma,
 — bone metastases,
 — angioinvasion and perineurium infiltration in his-
tologic examination.
2.2.2. Other duodenal neuroendocrine neoplasms
Clinical symptoms of other duodenal NENs are var-
ied: abdominal pain (in 9–64% of patients), bleeding 
from the upper gastrointestinal tract (in 11–28%), 
jaundice (in 7–32%), anaemia (in 11–28%), vomiting 
(4–8%) and duodenal stenosis (in 1% of patients). 
Jaundice, bile duct dilatation enlargement, vomiting 
and diarrhoea often accompany NENs located in the 
proximity of the ampulla of Vater [16]. If duodenal 
neuroendocrine neoplasms present symptoms of car-
cinoid syndrome (in case of hepatic metastasis), the 
syndrome is usually atypical [10] (described earlier, 
with gastric carcinoids).
Neuroendocrine neoplasms secreting  
ectopic hormones
In the literature there are reports describing duodenal 
neuroendocrine neoplasms with Cushing’s syndrome 
(5–15% of patients), predominantly already in IV 
stage of clinical advancement and with unfavourable 
prognosis, with acromegaly (ectopic GRH secretion), 
insulinoma and glucagonoma symptoms [17].
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2.2.3. Non-functional duodenal neuroendocrine 
neoplasms
They do not produce any hormone-dependent clinical 
symptoms. However, immunohistochemical examination 
demonstrates the presence of gastrin, serotonin, calci-
tonin and somatostatin in the tumour. These neoplasms 
constitute 70-98% of duodenal tumours. They include 
gangliocytic paragangliomas, which are most frequently 
located in the duodenal bulb area. They are usually large 
and benign tumours invading the muscular layer [18].
3. Diagnostics
3.1. Biochemical diagnostics
3.1.1. Gastric neuroendocrine neoplasms
Biochemical diagnostics of type 1 g-NENs:
 — increased serum chromogranin A (Cg) [19] (*evidence 
level 5);
 — high gastrin level under basic conditions [10] (*evi-
dence level 5);
 — increased daily urinary excretion (5-HIAA, 5-hydrox-
yindoleacetic acid) (*evidence level 5);
 — serum serotonin concentration. Determination should 
be performed only in patients with atypical (rarely 
with typical) carcinoid syndrome (*evidence level 5);
 — assessment of vitamin B12 level in patients with 
hypergastrinemia (*evidence level 3).
Determination of b-hCG, human chorionic gonado-
tropin (presence in the granules of tumour cells, possible 
ectopic secretion) may be useful for the diagnosis [18].
In biochemical diagnostics of type 2 NENs:
To confirm ZES, the following tests should be per-
formed:
 — serum gastrin level under basic conditions (*evidence 
level 3);
 — assessment of serum gastrin level after stimulation, 
i.e. the test with secretin (2 units/kg bw i.v.) or cal-
cium gluconate in uncertain cases, (*evidence level 3);
 — assessment of serum gastrin level in patients after 
surgery due to gastrinoma, 3–12 months after the 
surgery, then follow-up tests every 6–12 months for 
3–4 years (*evidence level 5).
Other:
 — determination of serum CgA concentration (*evi-
dence level 5);
 — in uncertain cases concerning differentiation of the 
causes of secondary hypergastrinemia — determi-
nation of gastric pH (pH< 2) [20] (*evidence level 4);
 — in the case of suspected MEN1 syndrome, screening 
tests described in "Diagnostic and therapeutic guide-
lines for gastro-entero-pancreatic neuroendocrine 
neoplasms (recommended by the Polish Network of 
Neuroendocrine Tumors)" (pp. 418–443) should be 
performed. Concomitant MEN1 syndrome requires 
confirmation in genetic tests [8] (*evidence level 4).
Biochemical diagnostics of type 3 NENs (NEC):
 — determination of serum CgA level is recommended 
(*evidence level 5);
 — daily urinary excretion of 5-HIAA in the case of 
atypical carcinoid syndrome (*evidence level 5).
3.1.2. Duodenal neuroendocrine neoplasms
 — determination of CgA (*evidence level 5);
 — gastrin in patients with ZES, in justified cases the 
test with secretin [19] (*evidence level 3);
 — if clinical symptoms suggestive of ectopic hormone 
production by duodenal NEN occur, the following 
hormones should be determined (regardless of clini-
cal symptoms characteristics): adrenocorticotropic 
hormone (ACTH) and cortisol, insulin and peptide 
C, as well as glucagon, insulin-like growth factor 1 
(IGF 1) and growth hormone (GH), also in functional 
tests [19] (*evidence level 5);
 — in patients with duodenal NEN and clinical charac-
teristics of MEN1 syndrome, positive family history 
of MEN1, and multi-focal duodenal NEN, genetic 
tests for the presence of germinal menin gene muta-
tion should be performed. Examination of somatic 
mutation in the tumour is not recommended [14] 
(*evidence level 4).
Minimal consensus statement on biochemical tests:
CgA — regardless of clinical symptoms (*evidence level 5);
Gastrin — in ZES (*evidence level 3);
5-HIAA — in typical and atypical carcinoid syndrome 
(*evidence level 3).
3.2. Pathomorphological diagnostics
3.2.1. Pathogenesis
Gastric NENs are usually non-functional tumours 
arising from enterochromaffin-like (ECL) cells produc-
ing histamine, and are most frequently found in the 
fundus and body of the stomach. Less common are 
gastrin-producing G cells, present in large quantities 
in the pylorus, somatostatin-producing D cells, dif-
fused in small quantities throughout the stomach, and 
serotonin-producing EC cells, very rarely found in the 
stomach. Gastric NENs are divided into four types, 
according to their clinical and morphological charac-
teristics [5, 21, 22]. Table I presents the characteristics 
of each group of neoplasms.
* evidence level according to CEBM [59]
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Type 1 gastric NENs occur most frequently. It de-
velops in the gastric mucosa in the course of atrophic 
gastritis with concomitant hypergastrinemia in the form 
of multiple polyps and nodules in the body of the stom-
ach. The precursor is a linear or nodular hyperplasia of 
ECL cells, associated with an increased risk of ECLoma. 
Type 1 tumours are usually benign and can disappear 
after resection of the prepyloric part, although currently 
this approach is not recommended [23].
Lymph nodes metastases are sporadic and usually 
develop in the course of tumours larger than 2 cm in di-
ameter. In the case of multiple gastric polyps, pathomor-
phological diagnosis requires differentiation of ECLoma 
from other lesions such as hyperplastic or inflammatory 
polyps, adenomas or early carcinoma type 0-I. Biopsy of 
different lesions is recommended, particularly of those 
which differ in macroscopic appearance, and from the 
fundus and body of the stomach, in order to verify 
atrophic inflammation.
Type 2 NENs are rare, and usually occur in the 
course of MEN1 with Zollinger-Ellison syndrome. Un-
like type 1, in 30% of cases lymph nodes metastases are 
present. The tumours are usually of more than 2 cm in 
diameter, invading muscularis propria and demonstrat-
ing angioinvasive properties.
Germinal mutation tests are recommended in pa-
tients with suspected MEN1 in cases with ECLoma and 
Zollinger-Ellison syndrome, or with a family history 
suggestive of MEN1 or multiple tumours without the 
evidence of atrophic gastritis. Examination of somatic 
mutations in gastric NENs is not recommended.
Gastric NENs type 1 and 2 are usually well-differen-
tiated neuroendocrine neoplasms (NEN G1, NEN G2).
Type 3, neuroendocrine carcinoma (NEC) is the sec-
ond most common gastric neuroendocrine neoplasm. 
It is a sporadic tumour, not associated with atrophic 
inflammation or hyperplasia of neuroendocrine cells. 
Neoplasms of more than 2 cm in diameter, angioinva-
sion and infiltration of the muscularis propria are the 
risk factors for metastasis.
Type 4, neuroendocrine carcinoma (NEC) is a spo-
radic, highly malignant neuroendocrine cancer, mani-
festing in the form of a large tumour mass, usually with 
metastases at the time of diagnosis. This neoplasm is 
characterised by unfavourable prognosis, fast progres-
sion and aggressive course.
3.2.2. Diagnostic algorithm
Diagnosis of gastric NENs is based on the histopatho-
logical examination of polyps after their endoscopic 
resection in the case of NENs type 1 and 2 (NEN G1, 
NEN G2), or the surgical material obtained after resec-
tion of the stomach and lymph nodes in gastric NENs 
type 3 and 4 (NECs) [7, 24–26].
A. Microscopic assessment of type 1 gastric NENs:
A type 1 gastric NEN is a well-differentiated neuroen-
docrine neoplasm with the macroscopic appearance of 
a polyp or polyps. In such cases, NEN G1 are usually 
diagnosed, and only sporadically NEN G2.
In microscopic assessment, the following parameters 
need to be determined:
 — type of the neoplasm according to the WHO clas-
sification;
 — differentiation grade G on the basis of the Ki-67/MIB1 
proliferation index and the number of mitotic figures;
Table I. Types of gastric neuroendocrine neoplasms
Tabela I. Typy nowotworów neuroendokrynnych żołądka
Type 1 Type 2 Type 3 Type 4
Frequency 70–80% rare 10–15% Rare
Size 0.5–1.0 cm Usually up to 1.5 cm Varied, most of them > 2 cm Large tumour mass
Number of tumours Multiple, small nodules, polyps Multiple Single Single
Location Body Body Throughout the stomach Throughout the 
stomach
Associated conditions Hypergastrinemia, 
chronic atrophic gastritis, 
ECL hyperplasia
MEN1 , hypergastrinemia, 
Zollinger-Ellison syndrome
Sporadic Sporadic
Clinical course Usually benign, 
limited to mucosa, submucosa
30% metastases 71% of tumours > 2cm 
Invasion of muscularis propria, 
vessels and lymph nodes
Highly malignant 
carcinoma, usually 
with metastases, 
unfavourable 
prognosis
Demographic characteristics 70–80% females
50–60 years of age
females = males
mean age 50 years
More frequently males
Mean age 55 years
More frequently 
males
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 — polyp resection margin;
 — angioinvasion properties.
B. Macroscopic assessment of surgical material 
includes the following parameters:
1. Size of the stomach fragment obtained for exami-
nation, with the description of the tumour’s location 
relative to resection margins.
2. Tumour size (if possible, in three dimensions). 
Condition of the mucosa at the tumour site (ulcerated/
non-ulcerated). Tumour position relative to the stomach 
wall layers; tumour cross-sectional image, taking into 
consideration the areas of necrosis and extravasations.
3. Number and size of lymph nodes.
4. Image of the mucosa in the remaining part of the 
slide (all changes need to be examined histopathologically).
5. Presence of other lesions in the stomach wall.
6. Width of surgical margins.
C. Microscopic assessment of the surgical material 
is based on the assessment of the following parameters:
1. Histological type of the NEN according to the 
WHO 2010 classification.
2. The histological grade G according to ENETS/ 
/WHO 2010.
3. Pathomorphological staging pTNM according to 
ENETS and AJCC/UICC (Table II).
4. Assessment of surgical margins.
5. Lesions in the gastric mucosa apart from the 
tumour:
 — presence/absence of atrophic inflammation,
 — hyperplasia of ECL cells,
 — other changes.
6. Assessment of immunohistochemical expression 
of neuroendocrine markers chromogranin A and syn-
aptophysin, as well the Ki67/MIB proliferative activity 
(obligatory)
7. Immunohistochemical assessment of the markers: 
NSE, CD56, CDX2, serotonin (conditional).
Histopathological types of NENs according to the 
WHO 2010 classification and the histological grade 
(G) according to the ENETS/WHO 2010 criteria are 
presented in "Diagnostic and therapeutic guidelines for 
gastro-entero-pancreatic neuroendocrine neoplasms 
(recommended by the Polish Network of Neuroendo-
crine Tumors)" (pp. 418–443).
Table II presents pTNM classification according to 
AJCC/UICC 2011.
3.2.3. Duodenal neuroednocrine neoplasms
Pathogenesis
Duodenal endocrine neoplasms are rare, constituting 
approximately 1–3% of primary neoplasms of this 
organ and 5.7–7.9% of gastrointestinal neuroendo-
crine neoplasms. Over 90% of NENs are located in 
the proximal duodenum, and approximately 20% in 
the vicinity of the ampulla of Vater [27, 28]. These 
neoplasms are usually small (up to 2 cm in diameter), 
single lesions limited to the mucosa and submucosa. 
Intramural, extensively infiltrating tumours up to 
5 cm [29, 30] have also been described. Multiple le-
sions, found in ca. 10% of cases, suggest the presence 
of MEN1 syndrome. In 40-60% of cases, regional 
lymph nodes metastases are found, and hepatic me-
tastases in less than 10% [24, 28, 31, 32].
Duodenal neuroendocrine neoplasms are more 
frequently tumours producing active substances than 
non-active ones. They include functional tumours 
such as gastrinoma (48% of cases) and somatostati-
noma (43%), as well as hormonally non-functional 
ones producing serotonin (27%) and calcitonin (9%). 
Approximately 50% of sporadic gastrin-producing 
NENs (G cell NENs) are hormonally functional tu-
mours, causing clinical gastrinoma syndrome and 
associated with Zollinger-Ellison syndrome. In 
patients with sporadic gastrinoma, approximately 
60–75% of neoplasms are located in the duodenum, 
and others in the pancreas. In MEN1 syndrome as-
sociated with Zollinger-Ellison syndrome, most gas-
trinoma tumours are located in the duodenum. The 
second type of duodenal neuroendocrine neoplasm, 
somatostatinoma, tends to arise near the ampulla of 
Vater, and in the microscopic picture is characterised 
by psammomatous bodies, usually not present in 
other duodenal NENs. According to the WHO clas-
sification, duodenal neuroendocrine neoplasms are 
usually well-differentiated NENs G1 (50% to 75% 
of cases), less often NEN G2 (25 to 50%), and only 
sporadically they are poorly differentiated neuroen-
docrine carcinomas (up to 3% of cases).
Grading of neuroendocrine neoplasms is conducted 
on the basis of mitotic activity (per ten high-power 
Table II. Classification pTNM according to UICC/AJCC, 2011
Tabela II. Klasyfikacja pTNM według UICC/AJCC, 2011
pT feature Comment
TX Primary tumour cannot be evaluated
T0 No evidence of primary tumour
Tis In situ tumour/neoplasm (< 0.5 cm), limited to mucosa
T1 Tumour invades mucosa and/or submucosa,  
tumour ≤ 1 cm
T2 Tumour invades muscularis propria or tumour > 1 cm
T3 Tumour invades subserosa
T4 Tumour invades serosa or other organs or adjacent 
structures
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fields) and proliferation activity measured using the 
Ki-67 index.
Diagnostic algorithm
A histopathological report from the assessment 
of the surgical material — duodenal neuroendocrine 
neoplasms:
A. Macroscopic description:
1. Size of the duodenum fragment obtained for 
examination, with the description of the tumour 
location relative to resection margins and surround-
ing tissues.
2. Tumour size (if possible, in three dimensions). 
Condition of the mucosa at the tumour site (ulcerated/ 
/non-ulcerated). Tumour position relative to the duo-
denal wall layers and adjacent tissues; tumour cross-
sectional image, taking into consideration the areas of 
necrosis and blood extravasations.
3. Number and size of lymph nodes.
4. Image of the mucosa in the remaining part of the 
slide (all changes need to be examined histopathologi-
cally).
5. Presence of other lesions in the duodenal wall.
B. Microscopic description:
1. Histopathological diagnosis (considering all the 
properties mentioned in the classification):
 — histological type according to the WHO 2010 clas-
sification;
 — histological grading (G) according to ENETS/WHO 
2010 (see General Recommendations for the Man-
agement of GEP NENs);
 — pTNM pathomorphological staging;
 — presence/absence of angioinvasion characteristics.
2. Tumour position relative to anatomical layers of 
the duodenal wall and adjacent tissue (depth of the 
invasion).
3. Width of surgical margins.
4. Lesions in the duodenal mucosa apart from the 
tumour.
5. Obligatory immunohistochemical examinations: 
chromogranin, synaptophysin and Ki-67/MIB1.
6. Conditionally — assessment of the neoplasm’s 
neuroendocrine properties in the immunohistochem-
ical examination (intensity and steadiness of reaction 
should be reported, and possibly, the manufacturer of 
the used reagents should be mentioned; in patients 
with MEN1 syndrome and gastrinoma located in 
the duodenum, immunohistochemical assessment of 
gastrin and other hormones expression, both in the 
primary tumour and in the metastatic foci, should 
be performed):
 — gastrin, serotonin, SST (additionally PP, calcitonin, 
insulin, glucagon);
 — S-100, NSE (in case of gangliocytic paraganglioma).
Fine-needle aspiration biopsy may be useful in the 
assessment of the stage of clinical advancement of the 
disease (diagnosis of neoplastic metastases in the lymph 
nodes and liver). Cytologic smears can also be used for 
immunocytochemical examinations.
TNM classification of duodenal neuroendocrine 
tumours [7]:
T — primary tumour
TX — primary tumour cannot be evaluated
T0 — no evidence of primary tumour
T1 — tumour invades lamina propria or submucosa 
and ≤ 1 in diameter (neoplasm limited to the ampulla 
of Vater for gangliocytic paraganglioma)
T2 — tumour invades muscularis propria or > 1 cm 
in diameter
T3 — tumour invades pancreas or retroperito-
neum
T4 — tumour invades visceral peritoneum or other 
organs (for any T, add ‘m’ with multiple tumours)
N — regional lymph nodes
NX — regional lymph nodes cannot be assessed
N0 — no regional lymph nodes metastases
N1 — presence of lymph nodes metastases
M — distant metastases
M — distant metastases cannot be assessed
M0 — no distant metastases
M1 — distant metastases
Clinical advancement staging is presented in 
Table III.
Minimal consensus statement on pathomorphological 
examination:
Minimal histopathological report for gastroduodenal 
NEN should include:
 — histological type of the neoplasm according to the WHO 
classification, considering the division into well-differ-
entiated neuroendocrine neoplasms (NEN G1 and NEN 
G2) and neuroendocrine carcinomas (NEC) or mixed 
neoplasms (MANEC);
 — histological G grading referring to well-differentiated 
neoplasms (NEN G1, NEN G2)
 — assessment of polyp resection or surgical margins in the 
surgical material;
 — pTNM histopathological staging according to ENET and 
AJCC/UICC classifications (it is important to provide 
affiliation of the classification in each case).
Histopathological diagnosis of NEN must be necessarily 
confirmed by immunohistochemical tests assessing expres-
* evidence level according to CEBM [59]
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sion of the neuroendocrine markers: synaptophysin and 
chromogranin A, as well as the Ki-67 proliferative activity 
using the MIB1 antigen (*evidence level 3).
3.3. Location diagnostics of gastroduodenal neu-
roendocrine neoplasms
3.3.1. Gastric neuroendocrine neoplasms
Gastric neuroendocrine tumours type 1:
 — basic examination in imaging diagnostics is en-
doscopy of the upper gastrointestinal tract with 
biopsy and/or complete removal of the largest 
tumour for histopathological examination; also 
two samples from the antrum need to be obtained 
for histopathological examination, as well as four 
samples from the fundus/body of the stomach [2, 
33, 34].
 — It is also recommended to obtain a biopsy from 
the antrum and from the body of the stomach 
for a quick urease test if Helicobacter pylori in-
fection was not assessed with the use of other 
methods;
 — in the case of tumours > 1–2 cm and/or multiple 
tumours, endoscopic ultrasonography (EUS) should 
be performed before deciding on endoscopic treat-
ment, in order to assess the depth of intramural 
invasion [6, 35].
To assess the disease staging, three-phase CT ex-
amination with water-filling of the stomach and after 
i.v. contrast administration needs to be performed as 
an initial (baseline) examination, and usually every 
six months, or depending on the clinical symptoms, 
as a surveillance examination during the clinical 
follow-up [36].
Gastric neuroendocrine tumours type 2:
 — similarly to type 1 tumours, endoscopy of the 
upper gastrointestinal tract with biopsy and/
or complete removal of a small tumour for 
histopathological examination should be per-
formed, also two samples from the antrum need 
to be obtained for histopathological examina-
tion, as well as four samples from the fundus/
body of the stomach in the case of larger and/ 
/or multiple tumours, and tests should be performed 
to determine the Helicobacter pylori infection;
 — in the case of tumours > 1–2 cm and/or multiple 
tumours, endoscopic ultrasonography (EUS) should 
be performed in order to assess the depth of intra-
mural invasion;
 — to exclude the presence of metastases, the following 
tests should be conducted:
• three-phase computed tomography (CT) ex-
amination with water-filling of the stomach 
and after i.v. contrast administration in order 
to determine the disease staging as an initial 
(baseline) examination, and usually every six 
months, or depending on the clinical symptoms, 
as a surveillance examination during clinical 
follow-up;
• SRS test in order to determine the disease 
staging during the follow-up, usually every 
9–12  months or depending on the clinical 
symptoms, and if discrepancies between clinical, 
biochemical and structural examination results 
occur. This test is necessary before introducing 
therapy with somatostatin analogues  (SSA) 
analogues (‘cold’ and ‘hot’).
In the case of gastric neuroendocrine neoplasms 
type 3 (sporadic) and type 4:
 — endoscopy of the upper gastrointestinal tract should 
be performed, and tumour samples obtained for 
diagnosis;
 — endoscopic ultrasonography (EUS) may be used to 
assess the depth of intramural invasion, the pres-
ence of lymph nodes metastasis, and to confirm 
the diagnosis in histopathological examination of 
fine-needle aspiration biopsy (FNAB) material;
Table III. Disease staging for duodenal neuroendocrine tumours
Tabela III. Stopień zaawansowania klinicznego nowotworów neuroendokrynnych dwunastnicy (staging)
Stage Feature T Feature N Feature M
I T1 N0 M0
IIa T2 N0 M0
IIb T3 N0 M0
IIIa T4 N0 M0
III any T N1 M0
IV any T anyN M1
* evidence level according to CEBM [59]
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 — ultrasonography (USG) of the abdominal cavity 
should be performed as an initial/surveillance ex-
amination (it enables identification of hepatic and 
lymph nodes metastasis with optimal conditions of 
examination of the abdominal cavity, mostly superfi-
cial lymph nodes or other superficial tissues invaded 
by the neoplastic process; it allows to obtain material 
for pathological examination, FNAB);
 — three-phase CT examination with water-filling of the 
stomach and after i.v. contrast administration should 
be performed each time in order to determine the 
disease staging, as an initial (baseline) examination, 
and as a surveillance examination during the clinical 
follow-up, usually every 3–6 months, or depending 
on the clinical symptoms;
 — magnetic resonance (MR) of the abdominal cavity 
before and after i.v. contrast administration should 
be performed if CT examination cannot be con-
ducted (allergy to iodine agents is not an absolute 
contraindication for the test, which may be per-
formed after proper antiallergenic premedication) 
[33, 37, 38]
 — magnetic resonance of the spine or bone scintigraphy 
should be performed if any osseous metastases, vis-
ible on the CT scan, are suspected. If numerous bone 
metastases are present, 99TcMDP scintigraphic exami-
nation should be performed to assess the possibility 
of palliative radioisotope therapy (*evidence level 3).
3.3.2. Duodenal neuroendocrine tumours:
 — a sensitive method for detecting duodenal neuroen-
docrine tumours is endoscopy of the upper gastro-
intestinal tract, conducted with the use of straight/ 
/curved probes with biopsy and/or complete remov-
al of the tumour for histopathological examination. 
In the case of hormonally functional tumours with 
characteristics of gastrinoma, upper gastrointestinal 
endoscopy may demonstrate specific lesions associ-
ated with gastric hypersecretion, such as multiple 
gastric and duodenal ulcers, and even small intes-
tinal ulcers or severe reflux oesophagitis (Zollinger-
Ellison syndrome) [33, 39].
 — endoscopic ultrasonography (EUS) with optional 
fine-needle aspiration biopsy should be performed 
in the case of larger tumours, in order to assess 
the extent of intramural invasion, and in any non-
diagnostic endoscopy [40–43].
To assess the disease staging, the following examina-
tions need to be performed:
 — three-phase computed tomography after oral 
administration of water in two stages — 500 mL 
half an hour before the test, and 500 mL imme-
diately before the test, for optimal expansion of 
the gastroduodenal lumen, and after i.v. contrast 
administration [36]. The test should be performed 
in order to determine the disease staging, as an 
initial (baseline) examination, and as a surveil-
lance examination during clinical follow-up, 
usually every six months, or depending on the 
clinical symptoms;
 — SRS test should be performed in order to deter-
mine the disease staging during follow-up, usually 
every 9–12 months, or depending on the clinical 
symptoms, and if discrepancies between clinical, 
biochemical and structural examination results oc-
cur. This test is necessary before introducing therapy 
with SSA (‘cold’ and ‘hot’).
 — if duodenal neuroendocrine tumours are not vis-
ible in structural and functional examinations, 
and in the case of hormonally functional tumours, 
intraoperative SRS and/or intraoperative USG are 
examinations of choice;
 — magnetic resonance of the spine or bone scintigra-
phy should be performed if any osseous metastases, 
visible in CT or SRS, are suspected [44] (*evidence 
level 3).
Minimal consensus statement on imaging:
Upper gastrointestinal endoscopy with histopathological 
examination of the obtained material and endoscopic ultra-
sonography are methods of choice in the diagnostics of most 
gastroduodenal neuroendocrine tumours.
Computed tomography of the abdominal cavity with con-
trast, magnetic resonance and receptor scintigraphy should 
be used to assess the disease staging and detect potential 
distant metastases.
In patients with advanced disease (e.g. with hepatic me-
tastases), bone scintigraphy, SRS and magnetic resonance of 
the spine should be performed (*evidence level 3).
4. Treatment
4.1. Endoscopic and surgical treatment  
of gastroduodenal neuroendocrine tumours
4.1.1. Gastric neuroendocrine tumours
1. Well-differentiated neoplasms of less than 
1  cm: only observation, necessary endoscopy every 
12 months.
2. Well-differentiated neoplasms larger than 1 cm, in 
EUS test not invading muscularis propria: endoscopic 
mucosal resection (EMR) or endoscopic mucosal dis-
section (ESD), or surgical resection, depending on 
* evidence level according to CEBM [59]
454
Gastroduodenal neuroendocrine tumours including gastrinoma	 	 Grażyna	Rydzewska	et	al.
the clinical situation. After endoscopic treatment, it is 
recommended to conduct surveillance examination 
every 12 months.
3. Neoplasms invading deep into the organ wall: 
surgical procedure of choice [6, 45].
4.1.2. Duodenal neuroendocrine tumours
If the disease is not metastatic, attempts should be made 
to remove all tumours within the duodenum.
In tumours smaller than 1 cm, not invading the mus-
cularis propria in the EUS examination, after exclusion 
of metastasis: if it is possible from the technical point 
of view, and we have access to a centre with proper 
experience, they may be removed endoscopically. If 
not – surgical removal is possible.
Tumours larger than 2 cm and any tumour with 
lymph nodes metastasis, regardless of its size, should 
be managed radically by surgical treatment.
Tumours of 1–2 cm:
 — without lymph nodes invasion: local excision,
 — with invasion of lymph nodes: radical surgical 
procedure.
Neoplasms with hepatic metastases: if surgical exci-
sion or local ablation of metastases is possible, radical 
surgical procedure within the duodenum should be 
performed [46, 47].
4.1.3. Gastrinoma
Sporadic gastrinoma:
 — if the disease is not disseminated, distal pancreatec-
tomy should be performed if the tumour is located 
in the peripheral part of the pancreas;
 — with the tumour located in the pancreatic head — 
if it is possible from the technical point of view, an 
attempt should be made to enucleate the tumour; 
if it is not possible, pancreatoduodenectomy should 
be performed;
 — with the tumour located in the duodenal wall it is 
necessary to perform duodenectomy with tumour 
excision or pancreatoduodenectomy.
Gastrinoma in MEN1 (most frequently multiple) — 
radical treatment is rarely possible. If the disease seems 
to be limited, an attempt to perform a radical resection 
can be made.
Minimal consensus statement on surgical treatment.
Surgery remains the only method with the potential to 
cure patients with neuroendocrine tumours of the stomach 
and duodenum. Tumours smaller than 1 cm and without signs 
of invasion can be observed in specialised centres. Tumours 
with a diameter of 1–2 cm can be excised locally by endos-
copy or open or laparoscopic surgery. Tumours with signs of 
invasion and metastatic lymph nodes, as well as all tumours 
larger than 2 cm, should be treated like cancer i.e. by extensive 
radical surgery. In gastrinoma, we should try to remove all 
tumours located in the pancreas or duodenum, usually by 
pancreatoduodenectomy (*evidence level 4).
4.2. Pharmacological treatment
4.2.2. Gastric neuroendocrine neoplasms
Gastric neuroendocrine neoplasms type 1
Patients with gastric NENs type 1 usually do not require 
pharmacological treatment [18]. Sometimes individual 
attempts are made to introduce treatment with somato-
statin analogues, as they inhibit hypergastrinemia and 
prevent hyperplasia of ECL cells [20] (*evidence level 4).
Gastric neuroendocrine neoplasms type 2
Zollinger-Ellison syndrome (ZES)
The aims of ZES therapy are: 1) to normalise secretion of 
hydrochloric acid, 2) to manage gastrinoma, 3) to treat 
gastric type 2 NEN (it develops in 13–30% of patients 
with ZES/MEN1) [8].
Excessive secretion of gastric acid in gastrinoma 
must be inhibited pharmacologically in all patients with 
gastrinoma, in order to prevent complications.
The treatment of choice involves proton pump inhibi-
tors (PPI) (*evidence level 3). All marketed PPI (omeprazole, 
lansoprazole, pantoprazole, rabeprazole, esomeprazole) 
reveal similar effectiveness. Administration of PPI once or 
twice a day is effective in most patients. The recommended 
initial dose for omeprazole in sporadic forms of ZES is 
60 mg once a day. In patients with ZES complications 
(MEN1 with hypercalcaemia, severe GERD symptoms, 
preceding Billroth II resection), higher doses of antisecre-
tive medications are used (e.g. omeprazole 40–60 mg twice 
a day). During a long-term therapy with PPI, the serum 
levels of vitamin B12 should be monitored once a year, and 
more frequent bone fractures in this population should 
be taken into account [15].
Histamine H2-receptor antagonists may also be used 
in patients with ZES. Patients with gastrinoma require 
higher and more frequent doses than patients with 
idiopathic peptic ulcer disease. If oral administration 
of medications is not possible, PPI are administered 
intravenously. During intravenous treatment, high 
doses of histamine H2-receptor antagonists are also 
administered by constant intravenous infusion.
Long-acting somatostatin analogues are not first-
line medications, and they should be used only in the 
case of PPI treatment-resistant, malignant gastrinoma 
(*evidence level 3).
* evidence level according to CEBM [59]
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In MEN1 syndrome, surgical resection of the para-
thyroids in primary hyperparathyroidism reduces ex-
cessive secretion of hydrochloric acid [16].
Gastric neuroendocrine neoplasms type 3 and 4
There is no specific pharmacological treatment. Therapy 
with SST analogues and biotherapy are not recommended 
in the case of these tumours (*evidence level 5). Rules 
for chemotherapy in NEC are described in "Diag nostic 
and therapeutic guidelines for gastro-entero-pancreatic 
neuroendocrine neoplasms (recommended by the Polish 
Network of Neuroendocrine Tumors)" (pp. 418–443).
In the case of progression of neuroendocrine neo-
plasms G1 and G2, the following are used [15, 48]:
 — therapy with short- or long-acting somatostatin 
analogues (*evidence level 3);
 — Everolimus 10 mg/day or sunitinib 37.5 mg/day in 
the case of gastrinoma (*evidence level 3); the other 
neoplasms: everolimus 10 mg/day (*evidence level 4);
 — cytotoxic chemotherapy if no other therapeutic 
options are available — capecitabine, dacarbazine, 
5-fluorouracil, interferon, temozolomide, or based 
on combinations containing streptozocin, 5-fluoro-
uracil and doxorubicin (*evidence level 4);
 — PRRT — see below.
Loperamide, cholestil, pancreatic enzymes, cholest-
yramine, biphosphonates and corticosteroids may be 
used for symptomatic treatment, according to clinical 
indications [15].
Chemotherapy in the treatment of poorly differen-
tiated gastric neuroendocrine neoplasms is similar to 
that used for therapy of small-cell carcinoma, i.e. the 
regimen based on the platinum derivatives (cisplatin or 
carboplatinum) and etoposide; in the case of progres-
sion, second-line chemotherapy should be considered 
(*evidence level 4).
4.2.3. Duodenal neuroendocrine neoplasms
Treatment of gastrinoma should be analogous to that 
of type 2 gastric NENs, whereas other tumours — in 
particular disseminated ones, associated with carcinoid 
syndrome — should be treated like gastric tumours at 
the same stage of advancement.
Chemotherapy in the treatment of poorly differenti-
ated duodenal neuroendocrine neoplasms is similar to 
that used for therapy of small-cell carcinoma.
Minimal consensus statement on pharmacotherapy:
1. Stomach
Type 1 — eradication of H. pylori (*evidence level 3).
Type 2 — eradication of H. pylori, PPI, (*evidence level 3).
In the case of malignant gastrinoma, treatment with 
somatostatin analogues to be considered (*evidence level 5).
Type 3 — symptomatic treatment, chemotherapy (*evi-
dence level 3).
2. Duodenum
ZES — PPI, H2 blockers (*evidence level 3).
ZES/MEN1 — PPI, treatment of hypercalcaemia (*evi-
dence level 3).
Hormonally non-functional neoplasms — symptomatic 
treatment (*evidence level 4).
Functional neoplasms — treatment specific for the type of 
hormonal activity, somatostatin analogues (*evidence level 3).
4.3. Radioisotope treatment
4.3.1. Duodenal neuroendocrine tumours
Isotope therapy with labelled somatostatin analogues is a 
form of palliative treatment rarely used in gastric NENs. 
The basic therapy in type 1 gastric NENs, whose form is 
usually polypoid, are endoscopic procedures, similarly to 
type 2 gastric NENs, which occur less frequently [49, 50].
Gastric neuroendocrine tumours type 1 are rarely 
associated with distant metastases, unlike type 2 gastric 
NENs, in which metastases can be present in 10–30% 
of patients already at the moment of diagnosis [49, 
51]. Despite a low proliferation index, NENs G1 tend 
to recur, and the median recurrence-free survival is 
24 months; however, the literature presents cases of 
transformation into NEC in 3% of patients [51]. The 
basic diagnostic tools in type 1 and 2 gastric NENs are 
endoscopy and EUS, used primarily to assess the depth 
of intramural invasion, mainly in tumours > 1–2 cm, 
before the endoscopic resection. Receptor scintigraphy 
examinations in these types of tumours do not show any 
significant clinical usefulness, except for less frequent 
large tumours, especially those invasive in EUS, or type 
2 NENs in MEN1 syndrome [50–52].
Apart from surgical treatment, chemotherapy is the ba-
sic treatment of gastric neuronendocrine neoplasms type 
3, in the case of disseminated disease [53]. Information 
on the possible use of targeted treatment with a labelled 
somatostatin analogue is very limited. The therapy may 
be introduced if high expression of somatostatin receptors 
on the neoplastic tumour cells is confirmed in a SPECT/ 
/PET examination, with somatostatin analogues in the 
case of disease progression/inoperative recurrence, and 
failure of other forms of treatment. Isotope diagnostics in 
this group of neoplasms enables determination of stag-
ing of the disease, and qualification to therapy with ‘hot’ 
somatostatin analogues; receptor scintigraphy performed 
after radionuclide therapy allows the assessment of its 
effectiveness [50, 54].
* evidence level according to CEBM [59]
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Among duodenal neuroendocrine tumours, the 
most frequently occurring ones are G1 tumours. G2 
are less common, and NEC are rare (< 3% of cases). 
Duodenal NENs G1 are rarely metastatic; in the case 
of G2 tumours, the risk of hepatic and lymph nodes 
metastases increases, and in NEC metastases are pre-
sent in 50–100% of cases. The basic form of therapy 
of duodenal NEN G1 and G2 is surgical treatment. 
To assess the staging of the disease, an imaging ex-
amination is performed during the follow-up, usu-
ally every 9–12 months, including the receptor test 
with a labelled somatostatin analogue. In metastatic 
duodenal G2 tumours, if surgical treatment of the 
primary tumour or metastases is impossible and the 
recurrence is inoperable, treatment with hot somato-
statin analogues may be implemented. Eligibility for 
treatment is based on the confirmation of somatostatin 
receptors expression in isotope tests, and the lack of 
contraindications for such therapy. Detailed informa-
tion on patient eligibility and PRRT can be found in 
the general section. It is also possible to apply this 
form of therapy in a case of a metastatic G1 tumour 
[9, 10, 18, 50, 51, 55–57].
In symptomatic tumours, treatment with ‘cold’ soma-
tostatin analogues should also be considered. In metastatic 
duodenal NEC, if chemotherapy fails and/or the disease 
progresses, and/or such treatment is not tolerated, targeted 
radioisotope therapy may be implemented, provided the 
receptor expression is high [18, 51, 53].
5. Summary
Isotope therapy is rarely used in gastric tumours. 
Information on this subject is very limited. It may be 
taken into consideration in the case of gastric NEC with 
progression of the disease/inoperative recurrence and 
failure of chemotherapy and/or intolerance of this type 
of treatment, if high expression of somatostatin recep-
tors is confirmed (*evidence level 4).
In duodenal G2/G1 tumours, isotope therapy may 
be considered as the first-line therapy in the case of 
progression of the disease, if surgical treatment is im-
possible (*evidence level 3).
In duodenal NEC, similarly to gastric G3 tumours, 
radionuclide therapy may be implemented if chemo-
therapy fails and/or the disease progresses, and/or 
such treatment is not tolerated, provided the receptor 
expression is high (*evidence level 4).
Minimal consensus statement on isotope treatment:
The basic form of therapy in duodenal tumours is surgical 
treatment.
In the case of well-differentiated neoplasms of 1–2 cm, not 
infiltrating the muscularis propria in EUS examination, 
endoscopic excision is possible (endoscopic resection or sub-
mucosal dissection).
Isotope therapy as the first-line treatment, with disease 
progression, particularly in duodenal G1 and G2 tumours.
In NEC, the treatment is considered individually, with pro-
gression of the disease and failure of other therapeutic methods, 
as well as with confirmed high expression of somatostatin 
receptors (*evidence level 4).
Monitoring of the treatment
Minimal consensus statement on follow-up [58]:
Biochemical tests
Stomach:
 — type 1 and type 2: 1–3 year — anamnesis and physical ex-
amination every 6–12 months; 4–10 year anamnesis and 
physical examination every 12 months (*evidence level 3);
type 3 and type 4:
 — 1 year: anamnesis and physical examination every 3–12 
months (*evidence level 3); CgA every — 3–12 months 
(*evidence level 5);
 — 2–10 year: anamnesis and physical examination every 
12 months (*evidence level 3), CgA every 12 months 
(*evidence level 5).
Duodenum:
 — first year: every 3–12 months anamnesis and physical 
examination, CgA (*evidence level 5);
 — 2–10 year: every 6–12 months anamnesis and physical 
examination (*evidence level 3), CgA (*evidence level 5).
Gastrinoma:
 — first year: every 3–12 months anamnesis and physical 
examination (*evidence level 3), gastrin (*evidence level 
3), CgA (*evidence level 5);
 — 2-10 year: every 6–12 months anamnesis and physical 
examination (*evidence level 3), gastrin (evidence level 
3), CgA (*evidence level 5).
Diagnostic imaging
Stomach: 
 — NEN type 1 and type 2: upper gastrointestinal endoscopy 
every 6–12 months, other imaging examinations (CT, 
MR) depending on the stage of the disease;
 — NEN type 3 and type 4: upper gastrointestinal endoscopy 
every 3–6 months, other imaging examinations (CT, MR) 
every 3–6 months.
Duodenum:
 — NEN G1, G2 — upper gastrointestinal endoscopy every 6–12 
months, other imaging examinations (CT, MR), depending 
on the stage of the disease, every 6–12 months;
 — NEC — upper gastrointestinal endoscopy every 3–6 
months, other imaging examinations (CT, MR) every 
3–6 months.
* evidence level according to CEBM [59]
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